Infinium Pharma

Why is Infinium Pharmachem Ltd falling/rising?

As of 09-Jun, Infinium Pharmachem Ltd's stock price is rising to 206.75, driven by outperformance against its sector and increased investor participation. However, it remains below its moving averages, indicating potential long-term downward trends despite short-term gains.

As of 09-Jun, Infinium Pharmachem Ltd's stock price is rising, currently at 206.75, reflecting an increase of 2.85 or 1.4%. This rise can be attributed to a few key factors. Firstly, the stock has outperformed its sector by 0.59% today, indicating a relative strength compared to its peers. Additionally, there has been a notable increase in investor participation, with a delivery volume of 3.5k on June 8, which is up by 6.06% compared to the 5-day average delivery volume. <BR><BR>However, it is important to note that despite the current rise, the stock is trading lower than its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This suggests that while there is a short-term upward movement, the longer-term trend may still be downward. Overall, the combination of today's outperformance and increased investor participation appears to be driving the stock's price upward in the short term.

Which are the latest news on Infinium Pharma?

Is Infinium Pharma overvalued or undervalued?

As of November 25, 2025, Infinium Pharma is fairly valued with a PE ratio of 43.23 and has underperformed the Sensex with a year-to-date return of -21.66%, indicating potential challenges in justifying its current price despite reasonable valuation compared to peers.

As of 25 November 2025, Infinium Pharma's valuation grade has moved from attractive to fair, indicating a shift in market perception. The company is currently fairly valued based on its financial metrics, with a PE ratio of 43.23, an EV to EBITDA of 23.31, and a ROE of 7.68%. Compared to its peers, Infinium Pharma's valuation appears reasonable; for instance, Sun Pharma is considered expensive with a PE of 36.81, while Cipla is attractive with a PE of 22.35.<BR><BR>Despite being fairly valued, Infinium Pharma has underperformed relative to the Sensex, with a year-to-date return of -21.66% compared to the Sensex's 9.47%. This underperformance, alongside its high valuation ratios, suggests that while the company is not overvalued, it may face challenges in justifying its current price in the near term.

How has been the historical performance of Infinium Pharma?

Infinium Pharma has demonstrated consistent growth in net sales, increasing from 99.12 Cr in March 2022 to 155.71 Cr in March 2025, but faced profitability challenges in the latest fiscal year, with profit after tax declining from 11.50 Cr in March 2024 to 7.84 Cr in March 2025. Total assets rose significantly, while cash flow from operating activities turned negative in March 2025.

Answer:<BR>The historical performance of Infinium Pharma shows a consistent growth trend in net sales and profits over the past four years.<BR><BR>Breakdown:<BR>Infinium Pharma's net sales have increased from 99.12 Cr in March 2022 to 155.71 Cr in March 2025, reflecting a steady upward trajectory. Total operating income followed a similar pattern, rising from 99.12 Cr to 155.71 Cr in the same period. However, total expenditure also grew, from 89.09 Cr in March 2022 to 139.29 Cr in March 2025, impacting operating profit which peaked at 20.07 Cr in March 2024 but fell to 18.54 Cr in March 2025. Profit before tax showed fluctuations, reaching 11.57 Cr in March 2025 after being 15.21 Cr in March 2024. The profit after tax decreased from 11.50 Cr in March 2024 to 7.84 Cr in March 2025. The company's total assets surged from 58.93 Cr in March 2022 to 198.24 Cr in March 2025, while total liabilities also increased significantly from 58.93 Cr to 198.24 Cr. Cash flow from operating activities turned negative in March 2025 at -29.00 Cr, contrasting with a positive cash flow in the previous years. Overall, while Infinium Pharma has shown growth in sales and assets, profitability has faced challenges in the latest fiscal year.

How big is Infinium Pharma?

As of 24th July, Infinium Pharmachem Ltd has a market capitalization of 422.00 Cr, classified as a Micro Cap, with no available financial data for Net Sales and Net Profit for the latest four quarters. As of March 2024, Shareholder's Funds are 58.78 Cr and Total Assets are 85.44 Cr.

As of 24th July, <BR><BR>Market Cap: Infinium Pharmachem Ltd has a market capitalization of 422.00 Cr, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales and Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 58.78 Cr and Total Assets totaling 85.44 Cr.

Who are the top shareholders of the Infinium Pharma?

The top shareholders of Infinium Pharma are Pravin Bhadabhai Madhani, the promoter with 12.2% ownership, and Ashish Kacholia, the highest public shareholder with 4.62%. Promoters hold the majority of shares, while individual investors own 32.0%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Infinium Pharma include Pravin Bhadabhai Madhani, who is the promoter with the highest holding at 12.2%. Additionally, Ashish Kacholia is the highest public shareholder, holding 4.62%. The majority of the company's shares are held by promoters, and individual investors collectively own 32.0% of the shares. There are currently no mutual funds or foreign institutional investors holding shares in the company.

Who are in the management team of Infinium Pharma?

As of March 2023, the management team of Infinium Pharma includes Sanjaykumar Viththalbhai Patel (Chairman & Managing Director), Pravin Bhadabhai Madhani, Mitesh Lavjibhai Chikhaliya (both Executive Directors), and independent directors Keyur Shah, Tarun Ratilal Dobariya, and Vaishakhi Ambrishbhai Shukla. Each member contributes to the company's governance and strategic direction.

As of March 2023, the management team of Infinium Pharma includes:<BR><BR>1. Sanjaykumar Viththalbhai Patel - Chairman & Managing Director<BR>2. Pravin Bhadabhai Madhani - Executive Director<BR>3. Mitesh Lavjibhai Chikhaliya - Executive Director<BR>4. Keyur Shah - Independent Director<BR>5. Tarun Ratilal Dobariya - Independent Director<BR>6. Vaishakhi Ambrishbhai Shukla - Independent Director<BR><BR>Each member plays a significant role in the governance and strategic direction of the company.

What is the technical trend for Infinium Pharma?

As of June 6, 2025, Infinium Pharma's technical trend is mildly bearish despite recent upward movement, with mixed signals from indicators like the bullish weekly MACD and bearish monthly RSI.

As of 6 June 2025, the technical trend for Infinium Pharma has changed from sideways to mildly bearish. The weekly MACD is bullish, but the monthly RSI indicates a bearish stance. Moving averages on the daily time frame are mildly bearish, while the weekly Dow Theory also supports a mildly bearish outlook. Bollinger Bands show a mildly bullish trend on both weekly and monthly time frames, which contrasts with the overall bearish sentiment. The stock is currently priced at 293.00, showing a recent upward movement from the previous close of 285.00, but the broader indicators suggest caution. Overall, the current technical stance is mildly bearish with mixed signals from various indicators.

What does Infinium Pharma do?

Infinium Pharmachem Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, incorporated in 2003 and converted to a public company in 2022. It currently has no available sales or profit data, with a market cap of Rs 454 Cr and a P/E ratio of 53.00.

Overview: <BR>Infinium Pharmachem Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Infinium Pharmachem Limited was originally incorporated as "Infinium Pharmachem Private Limited" in 2003. The company later converted to a Public Company and changed its name to "Infinium Pharmachem Limited" in August 2022. There is no recent sales or profit data available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: Rs 454 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 53.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 14.66% <BR>Price-to-Book: 7.79 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

When is the next results date for Infinium Pharma?

No Upcoming Board Meetings

What is the bonus history of the Infinium Pharma?

Infinium Pharma announced a 1:1 bonus issue, with an ex-date and record date of September 13, 2023, meaning shareholders will receive one additional share for each share they own. This is the latest update on their bonus history.

Infinium Pharma recently announced a bonus issue in a 1:1 ratio, with the ex-date being September 13, 2023. This means that shareholders will receive one additional share for every share they already own as of the record date, which is also September 13, 2023. This is the latest update regarding their bonus history. If you have any more questions about the company or its financial activities, feel free to ask!

Has Infinium Pharma declared dividend?

No Dividend History Available

Who are the peers of the Infinium Pharma?

Infinium Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Valiant Laborato, Brooks Lab, Zim Laboratories, Lyka Labs, and Everest Organics. Key insights show varying management risks, growth rates, and capital structures among these companies, with Everest Organics having the highest 1-year return at 245.22% and Valiant Laborato the lowest at -25.23%.

Peers: The peers of Infinium Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Valiant Laborato, Brooks Lab., Zim Laboratories, Lyka Labs, and Everest Organics.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Lyka Labs, while Average management risk is found at Zim Laboratories and Everest Organics. Below Average management risk is noted for Valiant Laborato and Brooks Lab. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Valiant Laborato, Brooks Lab., Zim Laboratories, and Everest Organics. Average growth is observed at Lyka Labs. In terms of Capital Structure, Excellent ratings are given to Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good to Torrent Pharma, and Below Average to Valiant Laborato, Brooks Lab., Lyka Labs, and Everest Organics, with Average for Zim Laboratories.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Everest Organics at 245.22%, while Valiant Laborato has the lowest at -25.23%. Infinium Pharma's 1-year return is 0.00%, which is significantly lower than both extremes. Additionally, the peers with negative six-month returns include Valiant Laborato, Zim Laboratories, Lyka Labs, and Everest Organics.